Article
IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy.
Nature genetics - 1 Oct 2009
Suppiah Vijayaprakash, Moldovan Max, Ahlenstiel Golo, Berg Thomas, Weltman Martin, Abate Maria Lorena, Bassendine Margaret, Spengler Ulrich, Dore Gregory J, Powell Elizabeth, Riordan Stephen, Sheridan David, Smedile Antonina, Fragomeli Vincenzo, Müller Tobias, Bahlo Melanie, Stewart Graeme J, Booth David R, George Jacob
Abstract excerpt
Hepatitis C virus (HCV) infects 3% of the world's population. Treatment of chronic HCV consists of a combination of PEGylated interferon-alpha (PEG-IFN-alpha) and ribavirin (RBV). To identify genetic variants associated with HCV treatment response, we conducted a genome-wide association study of sustained virological response (SVR) to PEG-IFN-alpha/RBV combination therapy in 293 Australian individuals with...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.